# | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
---|---|---|---|---|---|---|---|---|---|
1. | ALA4223800 | B | Inhibition of human SPT2 transfected in Freestyle293 cells using L-serine and palmitoyl-CoA as substrate preincubated for 60 mins followed by substrate addition measured after 15 mins by mass spectrometric analysis | Homo sapiens | 13 | cell-based format | Scientific Literature | ||
2. | ALA4223801 | F | Growth inhibition of human HCC4006 cells assessed as inflection point after 5 days by cell-titer-glo luminescent cell viability assay | Homo sapiens | 13 | assay format | Scientific Literature | ||
3. | ALA4223802 | A | Clearance in human liver microsomes in presence of NADPH | Homo sapiens | 6 | microsome format | Scientific Literature | ||
4. | ALA4223803 | A | Clearance in mouse liver microsomes in presence of NADPH | Mus musculus | 6 | microsome format | Scientific Literature | ||
5. | ALA4223804 | A | Oral bioavailability in non-fasted mouse at 1 mg/kg administered as cassette dosing by LC/MS/MS analysis | Mus musculus | 6 | organism-based format | Scientific Literature | ||
6. | ALA4223805 | B | Inhibition of SPT in human HCC4006 cells assessed as reduction in ceramide content after 24 hrs in presence of C16-ceramide-d31/C14-phosphatidylcholine-d72 by LC/MS analysis | Homo sapiens | 3 | cell-based format | Scientific Literature | ||
7. | ALA4223806 | F | Growth inhibition of human PL21 cells after 5 days by cell-titer-glo luminescent cell viability assay | Homo sapiens | 3 | assay format | Scientific Literature | ||
8. | ALA4223807 | P | Thermodynamic solubility in Japanese pharmacopoeia disintegration test solution 2 at 6.8 | 2 | small-molecule physicochemical format | Scientific Literature | |||
9. | ALA4223808 | A | Permeability of the compound from apical to basolateral side at pH 6.8 by PAMPA | 2 | assay format | Scientific Literature | |||
10. | ALA4223809 | A | Volume of distribution at steady state in non-fasted mouse at 0.1 mg/kg, iv administered as cassette dosing by LC/MS/MS analysis | Mus musculus | 2 | organism-based format | Scientific Literature | ||
11. | ALA4223810 | A | Total clearance in non-fasted mouse at 0.1 mg/kg, iv administered as cassette dosing by LC/MS/MS analysis | Mus musculus | 2 | organism-based format | Scientific Literature | ||
12. | ALA4223811 | A | Cmax in non-fasted mouse at 1 mg/kg, po administered as cassette dosing by LC/MS/MS analysis | Mus musculus | 2 | organism-based format | Scientific Literature | ||
13. | ALA4223812 | A | Tmax in non-fasted mouse at 1 mg/kg, po administered as cassette dosing by LC/MS/MS analysis | Mus musculus | 2 | organism-based format | Scientific Literature | ||
14. | ALA4223813 | A | AUC in non-fasted mouse at 1 mg/kg, po administered as cassette dosing by LC/MS/MS analysis | Mus musculus | 2 | organism-based format | Scientific Literature | ||
15. | ALA4223814 | A | MRT in non-fasted mouse at 1 mg/kg, po administered as cassette dosing by LC/MS/MS analysis | Mus musculus | 2 | organism-based format | Scientific Literature | ||
16. | ALA4223815 | F | In vivo inhibition of SPT in tumors of human HCC1806 cells xenografted in mouse assessed as reduction in 3-KDS levels at 10 mg/kg, po measured after 8 hrs post dose by LC/MS analysis relative to control | Mus musculus | 2 | organism-based format | Scientific Literature |